Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Salivary gland cancer; Solid tumours
- Focus First in man; Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 18 Jan 2024 Status changed from active, no longer recruiting to completed.
- 07 Sep 2023 Planned End Date changed from 30 Sep 2023 to 31 Mar 2024.
- 04 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.